Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000953 · ClinicalTrials.gov registry record · Phase 2
Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00000953 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 180 participants.
The verdict
NCT00000953, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of localized herpes zoster in HIV-infected patients. HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used to treat VZV infections in the HIV population. Since no data from controlled studies are available to define the role of antiviral therapy for VZV infections in HIV-infected patients, a study is needed to test the relative efficacy of brovavir, an experimental antiviral drug, versus that of acyclovir.
Interventions
- DRUG Acyclovir
- DRUG Sorivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000953
The ClinicalTrials.gov registry entry for NCT00000953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acyclovir is the first listed.
NCT00000953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000953 about?
NCT00000953 is a clinical study titled "Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients". To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of localized herpes zoster in HIV-infected patients. HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an...
What is the current status of trial NCT00000953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants.
What interventions are being tested in trial NCT00000953?
The interventions under investigation include: Acyclovir (DRUG), Sorivudine (DRUG).
Who is sponsoring clinical trial NCT00000953?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.